Drug Trial News

RSS

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.

22 Dec 2020

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston.

21 Dec 2020

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody.

18 Dec 2020

Study recommends blinded crossover and continued follow-ups to evaluate SARS-CoV-2 vaccine durability

A new multicenter study has shown that blinded crossover and continued follow-up of trial participants can help assess vaccine durability and potential delayed enhancement of disease.

18 Dec 2020

FDA approves pembrolizumab as first-line treatment for colorectal cancer

The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with certain types of advanced colorectal cancer. This is the 9th FDA approval supported by Stand Up To Cancer® (SU2C) research.

18 Dec 2020

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study

Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal.

17 Dec 2020

Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity

Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington's Disease.

17 Dec 2020

LOOP technique is an effective alternative for treating skin abscesses

The LOOP technique for incision and drainage (I&D) of abscesses in adults is a safe and effective alternative to the traditional I & D with packing and may offer an alternative to the standard regimen in the treatment of uncomplicated skin abscesses in pediatric patients.

17 Dec 2020

BAT advances COVID-19 vaccine candidate into phase-I clinical trial

The COVID-19 vaccine candidate (KBP-COVID-19; NCT04473690) will become one of a number of potential vaccines to have progressed beyond pre-clinical testing.

16 Dec 2020

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.)

16 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.

15 Dec 2020

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine.

11 Dec 2020

First patient participates in immunotherapy trial despite COVID-19 pandemic

Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing has successfully eradicated the disease.

11 Dec 2020

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

South African study data were used to evaluate the safety of the vaccine in the results just published, but not its efficacy [which refers to the percentage reduction of disease].

9 Dec 2020

New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage breast cancer patients

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health.

8 Dec 2020

Previous
1
...
76
77
78
79
80
81
82
...
1158
Next

Drug Trial News

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Study recommends blinded crossover and continued follow-ups to evaluate SARS-CoV-2 vaccine durability

FDA approves pembrolizumab as first-line treatment for colorectal cancer

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study

Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity

LOOP technique is an effective alternative for treating skin abscesses

BAT advances COVID-19 vaccine candidate into phase-I clinical trial

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

RedHill Biopharma announces promising preliminary results from opaganib study

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

First patient participates in immunotherapy trial despite COVID-19 pandemic

Combination therapy places no greater burden on early-stage breast cancer patients

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage breast cancer patients

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News